Form D · Biotechnology
VitriVax, Inc.
Boulder, CO · CIK 0001965109
Offering snapshot reported Nov 17, 2025 · SEC filing
- Reported sold
- $29.4M Offering amount: $37.1M
- Investors reported
- 83 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 17, 2025 | Initial | $29,430,356 | No comparison | 83 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564197
Total Offering Amount includes conversion of convertible promissory notes.
Source: Form D, filed Nov 17, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Louise Brady | Director |
| Romulo Colindres | Director, Executive, Promoter |
| Rene Lorenz | Director |
| Theodore Randolph | Director |
| Glenn Rockman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5500 Central Avenue
Boulder, CO, 80301
Boulder, CO, 80301